(thirdQuint)TCD Followed by autoSCT for Newly Diagnosed MM Patients.

 Phase II clinical trial for the patients with newly diagnosed.

 TCD (thalidomide, cyclophosphamide and dexamethasone) will be applied for the patients as an induction chemotherapy, followed by high dose chemotherpy and autologous stem cell transplantation.

 Afterthen, they will receive TD (thalidomide and dexamethasone) maintenance therapy for one year.

.

 TCD Followed by autoSCT for Newly Diagnosed MM Patients@highlight

Multiple Myeloma is a incurable disease.

 Thalidomide in combination with other agents are currently in trials for the newly diagnosed patients, we designed treatment of TCD, followed by high dose chemotherapy with autologous stem cell transplantation and TD maintenance therapy for the patients with newly diagnosed multiple myeloma.

